Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone + Decitabine + Cytarabine (D-CMG) in Elderly AML
NCT06651866Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Maximum Tolerated Dose up to 24 months. Started Dec 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06651866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651866.